ePS03.1 Disease progression in patients (pts) with cystic fibrosis (CF) treated with ivacaftor (IVA): analysis of real-world data from the UK CF Registry

How Clinically Efficient Are Lumacaftor/Ivacaftor for Cystic Fibrosis Patients: An Updated Literature Review

“…They included 9936 participants with IVA in 2014 of the US and UK CF registry. This study yielded a lower rate of PEx, Hospitalization, death rate, and organ-transplantation in the IVA group [ 34 ]. A summary of the studies showing an overview of the effects on HRQoL and BMI is shown in Table 2 .…”

“…They included 9936 participants with IVA in 2014 of the US and UK CF registry. This study yielded a lower rate of PEx, Hospitalization, death rate, and organ-transplantation in the IVA group[34]. A summary of the studies showing an overview of the effects on HRQoL and BMI is shown inTable 2.Scores on the CFQ-R were calculated 8 out of the total 12 domains of HRQoL within the first week of PEx.Several weeks were required for a full recovery to reach pre PEx levels in CF patients.…”